Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS)

- Post hoc EXPAND analysis showed improvements in cognitive processing speed in patients with active and non-active SPMS treated with Mayzent¹

- Subgroup analyses of the EXPAND trial showed the value of early treatment initiation with Mayzent in patients with active SPMS as positive effects on disability, cognitive processing speed and relapse outcomes were sustained for up to five years²

- Results from EXCHANGE interim analysis presented at ACTRIMS-ECTRIMS reinforced its safety and tolerability profile when patients switched from an oral or injectable disease-modifying therapy (DMT) to Mayzent³

Basel, September 11, 2020 — Novartis announced today that Mayzent® (siponimod) analyses from the Phase IIIb EXCHANGE and EXPAND trials showed Mayzent to be a safe treatment option that has benefits in cognitive performance and reduces the risk of disability progression in patients with progressing MS¹-³. The data were presented at the MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting that is taking place September 11–13, 2020.

“One of the biggest goals for people living with MS is to be able to live their lives independently for as long as possible,” said Norman Putzki, MD, Global Head of Development, Neuroscience. “The data presented today reinforces that through its beneficial effects on cognitive performance and delaying disability progression, and as an appropriate option for patients to safely switch to/from other treatments, Mayzent offers hope for people looking to achieve this important goal.”

The EXCHANGE study is a Phase IIIb prospective, six-month open-label study evaluating the safety and tolerability of conversion to Mayzent from other disease-modifying therapies (DMTs) in patients with relapsing multiple sclerosis (RMS), including active secondary progressive multiple sclerosis (SPMS). The interim analysis included 112 patients from 42 centers in the US who were eligible for the safety analysis³. The EXPAND study is a randomized, double-blind, placebo-controlled Phase III study, comparing the efficacy and safety of Mayzent versus placebo in patients with SPMS with varying levels of disability. The post hoc EXPAND analysis found that in patients with active disease, an increased chance for clinically relevant improvement was observed and patients with active SPMS early and
continuously treated with Mayzent experienced lower risk of disability progression and
cognitive decline than patients who delayed Mayzent treatment\textsuperscript{1,2}.

\textbf{Disclaimer}
This media update contains forward-looking statements within the meaning of the United
States Private Securities Litigation Reform Act of 1995. Forward-looking statements can
generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,”
“would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,”
“pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential
marketing approvals, new indications or labeling for the investigational or approved products
described in this media update, or regarding potential future revenues from such products.
You should not place undue reliance on these statements. Such forward-looking statements
are based on our current beliefs and expectations regarding future events, and are subject to
significant known and unknown risks and uncertainties. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those set forth in the forward-looking statements. There can be no
guarantee that the investigational or approved products described in this media update will be
submitted or approved for sale or for any additional indications or labeling in any market, or at
any particular time. Nor can there be any guarantee that such products will be commercially
successful in the future. In particular, our expectations regarding such products could be
affected by, among other things, the uncertainties inherent in research and development,
including clinical trial results and additional analysis of existing clinical data; regulatory actions
or delays or government regulation generally; global trends toward health care cost
containment, including government, payor and general public pricing and reimbursement
pressures and requirements for increased pricing transparency; our ability to obtain or
maintain proprietary intellectual property protection; the particular prescribing preferences of
physicians and patients; general political, economic and business conditions, including the
effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data
integrity or manufacturing issues; potential or actual data security and data privacy breaches,
or disruptions of our information technology systems, and other risks and factors referred to in
Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission.
Novartis is providing the information in this media update as of this date and does not
undertake any obligation to update any forward-looking statements contained in this media
update as a result of new information, future events or otherwise.

\textbf{About Novartis}
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global
medicines company, we use innovative science and digital technologies to create
transformative treatments in areas of great medical need. In our quest to find new medicines,
we consistently rank among the world’s top companies investing in research and
development. Novartis products reach nearly 800 million people globally and we are finding
innovative ways to expand access to our latest treatments. About 109,000 people of more
than 140 nationalities work at Novartis around the world. Find out more at

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact media.relations@novartis.com

\textbf{References}
active and non-active disease. ePoster presentation at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting;
September 2020
siponimod treatments in patients with active SPMS: EXPAND data up to 5 years. ePoster presentation at
MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting; September 2020

Novartis Media Relations
E-mail: media.relations@novartis.com

Antonio Ligi  Michael Amos
Novartis External Communications Novartis Global Pharma Communications
+41 79 723 3681 (mobile) +41 61 324 2705 (direct)
antonio.ligi@novartis.com +41 79 123 7806 (mobile)

Eric Althoff
Novartis US External Communications
+1 862 778 3243
+1 646 438 4335
eric.althoff@novartis.com

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

Central  North America
Samir Shah  +41 61 324 7944  Sloan Simpson  +1 862 778 5052
Thomas Hungerbuehler  +41 61 324 8425
Isabella Zinck  +41 61 324 7188